Literature DB >> 11883844

Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism.

Vladimir V Didenko1, Hop N Ngo, Candace Minchew, David S Baskin.   

Abstract

OBJECT: The goal of this study was to investigate whether apoptosis occurs in T lymphocytes that invade Fas ligand (FasL)-expressing glioblastomas multiforme (GBMs) and if its induction could be mediated by Fas.
METHODS: Apoptotic T lymphocytes were detected in GBMs by using detection of cell-type markers combined with active caspase-3 immunohistochemical analysis, a recently introduced apoptosis-specific in situ ligation assay, as well as by examining morphological criteria. Apoptotic T cells expressed Fas and were localized in the vicinity or in direct contact with FasL-expressing tumor cells. The T lymphocytes were undergoing apoptosis in spite of Bcl-2 expression. Expression of Bax was also detected in dying T cells, which can explain the absence of the protective effect of Bcl-2. because Bax inhibits Bcl-2 death-repressor activity.
CONCLUSIONS: On the basis of the data presented in this paper, the authors suggest that GBM cells that express FasL can induce apoptosis in invading immune cells. This phenomenon may play an important role in these tumors' maintenance of immune privilege and evasion of immune attacks. Awareness of this phenomenon should be helpful for the development of novel strategies for treatment of malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11883844      PMCID: PMC1853267          DOI: 10.3171/jns.2002.96.3.0580

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  19 in total

1.  Substantial background reduction in ligase-based apoptosis detection using newly designed hairpin oligonucleotide probes.

Authors:  V V Didenko; D J Boudreaux; D S Baskin
Journal:  Biotechniques       Date:  1999-12       Impact factor: 1.993

2.  Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors.

Authors:  C Gratas; Y Tohma; E G Van Meir; M Klein; M Tenan; N Ishii; O Tachibana; P Kleihues; H Ohgaki
Journal:  Brain Pathol       Date:  1997-07       Impact factor: 6.508

3.  Quantification of Bax/Bcl-2 ratios in peripheral blood lymphocytes, monocytes and granulocytes and their relation to susceptibility to anti-Fas (anti-CD95)-induced apoptosis.

Authors:  H J Van Der Vliet; P C Wever; F N Van Diepen; S L Yong; I J Ten Berge
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

4.  A cautionary note on the use of the TUNEL stain to determine apoptosis.

Authors:  C Charriaut-Marlangue; Y Ben-Ari
Journal:  Neuroreport       Date:  1995-12-29       Impact factor: 1.837

5.  Human astrocytomas co-expressing Fas and Fas ligand also produce TGFbeta2 and Bcl-2.

Authors:  B Frankel; S L Longo; T C Ryken
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

6.  Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin.

Authors:  Y Mizutani; M Nakao; O Ogawa; O Yoshida; B Bonavida; T Miki
Journal:  J Urol       Date:  2001-01       Impact factor: 7.450

7.  Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

Authors:  S Strand; W J Hofmann; H Hug; M Müller; G Otto; D Strand; S M Mariani; W Stremmel; P H Krammer; P R Galle
Journal:  Nat Med       Date:  1996-12       Impact factor: 53.440

8.  Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

Authors:  P Saas; P R Walker; M Hahne; A L Quiquerez; V Schnuriger; G Perrin; L French; E G Van Meir; N de Tribolet; J Tschopp; P Y Dietrich
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

9.  Presence of double-strand breaks with single-base 3' overhangs in cells undergoing apoptosis but not necrosis.

Authors:  V V Didenko; P J Hornsby
Journal:  J Cell Biol       Date:  1996-12       Impact factor: 10.539

10.  The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.

Authors:  J O'Connell; G C O'Sullivan; J K Collins; F Shanahan
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

View more
  27 in total

Review 1.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

Review 2.  Combining immunotherapy with radiation for the treatment of glioblastoma.

Authors:  Kevin K H Chow; Wendy Hara; Michael Lim; Gordon Li
Journal:  J Neurooncol       Date:  2015-04-17       Impact factor: 4.130

3.  Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma.

Authors:  Li-Ning Xu; Sheng-Quan Zou; Jian-Ming Wang
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

Review 4.  T-cell Dysfunction in Glioblastoma: Applying a New Framework.

Authors:  Karolina I Woroniecka; Kristen E Rhodin; Pakawat Chongsathidkiet; Kristin A Keith; Peter E Fecci
Journal:  Clin Cancer Res       Date:  2018-03-28       Impact factor: 12.531

Review 5.  Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.

Authors:  Neha Kamran; Mayuri Chandran; Pedro R Lowenstein; Maria G Castro
Journal:  Clin Immunol       Date:  2016-10-21       Impact factor: 3.969

6.  Protein expression of Fas, Fas ligand, Bcl-2 and TGFbeta2 and correlation with survival in initial and recurrent human gliomas.

Authors:  Rainer J Strege; Christian Godt; Andreas M Stark; Heinz-Hermann Hugo; H Maximilian Mehdorn
Journal:  J Neurooncol       Date:  2004 Mar-Apr       Impact factor: 4.130

7.  FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors.

Authors:  Ivy A Ho; Wai H Ng; Paula Y Lam
Journal:  Mol Cancer       Date:  2010-10-13       Impact factor: 27.401

Review 8.  Overview of current immunotherapeutic strategies for glioma.

Authors:  Anda-Alexandra Calinescu; Neha Kamran; Gregory Baker; Yohei Mineharu; Pedro Ricardo Lowenstein; Maria Graciela Castro
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

Review 9.  Single vs. combination immunotherapeutic strategies for glioma.

Authors:  Mayuri Chandran; Marianela Candolfi; Diana Shah; Yohei Mineharu; Viveka Nand Yadav; Carl Koschmann; Antonela S Asad; Pedro R Lowenstein; Maria G Castro
Journal:  Expert Opin Biol Ther       Date:  2017-03-20       Impact factor: 4.388

Review 10.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.